Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin once a week. The placebo is a treatment with no active medicine in it and will be given to all participants. In addition to placebo, participants will receive either of the active medicine NNC0487-0111 (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator). Which treatment participants get is decided by chance.
Key Inclusion Criteria:
Key Exclusion Criteria:
clinicaltrials@novonordisk.com(+1) 866-867-7178
Capital Federal, Buenos Aires C1056ABI, Argentina
Porto Alegre, Rio Grande do Sul 90430-001, Brazil
Grad Zagreb, 10000, Croatia
Krapinske Toplice, 49217, Croatia
Pohlheim, 35415, Germany
Budapest, Pest County 1036, Hungary
Aligarh, 202002, India
Thriruvananthapuram, 695 032, India
Lublin, Lesser Poland Voivodeship 20-064, Poland
Bialystok, 15-435, Poland
Ruda Śląska, 41-709, Poland
Senhora Da Hora, Matosinhos, 4464-513, Portugal
Bucharest, Bucharest 020475, Romania
Adana /yüreği̇r, 01240, Turkey (Türkiye)
Battalgazi / Malatya, 44280, Turkey (Türkiye)
Pendik/istanbul, 34899, Turkey (Türkiye)
Yüreğir/Adana, 1370, Turkey (Türkiye)